Lex Machina, a leader in legal analytics and a LexisNexis company, unveiled an API Developer Portal.

A federal judge in Delaware tossed out a lawsuit by Roche company Genentech accusing Novartis’ Sandoz division of patent infringement. In this case, the patent was related to Genentech’s Esbriet (pirfenidone), which is used to treat idiopathic pulmonary fibrosis.

Bayer

Bayer AG reached an $80 million settlement with Ohio to resolve environmental damage allegedly caused by polychlorinated biphenyls (PCBs) made by the company’s Monsanto business, the state attorney general said on March 24.

A federal judge on March 21 said Apple Inc. must face a Silicon Valley company’s claims it illegally monopolized the U.S. market for heart rate monitoring apps for the Apple Watch.

Bristol Myers Squibb

Bristol Myers Squibb Co., in a lawsuit made public on March 17, said AstraZeneca’s cancer treatment Imfinzi violates patents related to the company’s blockbuster cancer drug Opdivo.

Alnylam is suing both Moderna and Pfizer over what it claims are patent infringements related to the Cambridge, Massachusetts-based company’s biodegradable cationic lipids that it says have been foundational to the success of the mRNA-based COVID-19 vaccines developed by the two companies.

Biogen

A decision made by the U.S. Court of Appeals for the Federal Circuit delivered a blow to Biogen Inc., denying a second look into the patent dispute filed against Mylan Pharmaceuticals Inc.

Rhode Island was set to square off on March 14 against Teva Pharmaceutical Industries Ltd., as a multibillion-dollar trial begins over whether the Israeli company contributed to an opioid crisis that has caused more than 500,000 deaths over the past two decades.

The Sackler family owners of Purdue Pharma LP reached a deal with nine state attorneys general to pay up to $6 billion in cash to resolve widespread litigation alleging that they fueled the U.S. opioid epidemic, bringing the OxyContin maker closer to exiting bankruptcy.

U.S. Bankruptcy Court Judge Michael Kaplan ruled that Johnson & Johnson be allowed to continue with the company’s controversial spinoff strategy to settle with people who filed lawsuits claiming that J&J’s talc-based baby powder causes cancer.